| Title: |
Risk factors of de novo malignancies after liver transplantation: a french national study on 11004 adult patients |
| Authors: |
Altieri, Mario; Seree, Olivier; Lobbedez, Thierry; Segol, Philippe; Abergel, Armand; Blaizot, Xavier; Boillot, Olivier; Boudjema, Karim; Coilly, Audrey; Conti, Filomena; Chazouilleres, Olivier; Debette-Gratien, Maryline; Dharancy, Sebastien; Durand, Francois; Duvoux, Christophe; Francoz, Claire; Gugenheim, Jean; Hardwigsen, Jean; Houssel-Debry, Pauline; Kamar, Nassim; Latournerie, Marianne; Lebray, Pascal; Leroy, Vincent; Neau-Cransac, Martine; Pageaux, Georges-Philippe; Radenne, Sylvie; Salame, Ephrem; Saliba, Faouzi; Samuel, Didier; Vanlemmens, Claire; Besch, Camille; Launoy, Guy; Dumortier, Jerome |
| Contributors: |
CHU Lille; Inserm; Université de Lille; Hôpital Côte de Nacre CHU Caen; Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers ANTICIPE; Réseau régional de cancérologie de la région Normandie OncoNormandie; Registre de Dialyse Péritonéale de Langue Française et Hémodialyse à Domicile Pontoise RDPLF-HDD; Centre Universitaire des Maladies Rénales CHU Caen CUMR Caen; CHU Estaing Clermont-Ferrand; Institut Pascal IP; Hôpital Edouard Herriot CHU - HCL; Université Claude Bernard Lyon 1 UCBL; Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou; Centre Hépato-Biliaire Hôpital Paul Brousse CHB; Physiopathogénèse et Traitement des Maladies du Foie; CHU Pitié-Salpêtrière AP-HP; Centre de Recherche Saint-Antoine CRSA; CHU Saint-Antoine AP-HP; Service d'Hépato-gastro-entérologie et Nutrition CHU Dupuytren 1, Limoges; Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation IPPRITT; Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286; Hôpital Beaujon AP-HP; Centre de recherche sur l'Inflammation CRI (UMR_S_1149 / ERL_8252 / U1149); Hôpital Henri Mondor; Service d’Hépatologie Hôpital Beaujon; Université de Nice Sophia-Antipolis UNSA; Service de Chirurgie Digestive / Centre de Transplantation Hépatique CHU Nice; Hôpital de la Timone CHU - APHM TIMONE; Département de Néphrologie et Transplantation d'organes CHU Toulouse; Epidémiologie et recherche clinique en oncologie digestive (CTM UMR 1231) EPICAD; Service d'hépato-gastroentérologie et cancérologie digestive (CHU de Dijon); Centre Hospitalier Universitaire CHU Grenoble CHUGA; Hôpital Haut-Lévêque CHU Bordeaux; Département d'Hépato-Gastroentérologie et de Transplantation Hépatique CHU Saint-Eloi; Service d'Hépatologie Hôpital de la Croix-Rousse - HCL; CHU Trousseau Tours; Physiopathologie et traitement des maladies du foie; Hôpital JeanMinjoz; Pôle des Pathologies Digestives Hépatiques et Transplantation Hôpital Hautepierre-Strasbourg; Université de Caen Normandie UNICAEN |
| Publication Year: |
2024 |
| Collection: |
LillOA (Lille Open Archive - Université de Lille) |
| Description: |
BACKGROUND: After liver transplantation (LT),de novo malignancies are one of the leading causes of late mortality. The aim of the present retrospective study was to identify the risk factors of de novo malignancies in a large cohort of LT recipients in France, using Fine and Gray competing risks regression analysis. METHODS: The study population consisted in 11004 adults transplanted between 2000 and 2013, who had no history of pre-transplant malignancy, except primary liver tumor. A Cox model adapted to the identification of prognostic factors (competitive risks) was used. RESULTS: From the entire cohort, one (or more)de novo malignancy was reported in 1480 L T recipients (13.45%). The probability to develop a de novo malignancy after LT was 2.07% at 1 year, 13.30% at 5 years, and 28.01% at 10 years. Of the known reported malignancies, the most common malignancies were hematological malignancy (22.36%), non-melanoma skin cancer (19.53%) and lung cancer (12.36%). According to Fine and Gray competing risks regression multivariate analysis, were significant risk factors for post-LT de novo malignancy: recipient age (Subdistribution Hazard Ratio (SHR) = 1.03 95%CI 1.03-1.04), male gender (SHR = 1.45 95%CI 1.27-1.67), non-living donor (SHR = 1.67 95%CI 1.14-2.38), a first LT (SHR = 1.35 95%CI 1.09-1.69) and the type of initial liver disease (alcohol-related liver disease (SHR = 1.63 95%CI 1.22-2.17), primary sclerosing cholangitis (SHR = 1.98 95%CI 1.34-2.91), and primary liver tumor (SHR = 1.88 95%CI 1.41-2.54)). Initial immunosuppressive regimen had no significant impact. CONCLUSIONS: The present study confirms that LT recipient characteristics are associated with the risk ofde novo malignancy and this underlines the need for personalized screening in order to improve survival. ; 45 |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/octet-stream |
| Language: |
English |
| Relation: |
Clinics and Research in Hepatology and Gastroenterology; Clin Res Hepatol Gastroenterol; http://hdl.handle.net/20.500.12210/40493 |
| Availability: |
https://hdl.handle.net/20.500.12210/40493 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.DA6B72F |
| Database: |
BASE |